LY-544344. Eli Lilly.
Eli Lilly and Co is developing LY-544344, a prodrug of the metabotropic glutamate receptor 2/3 agonist LY-354740, for the potential treatment of anxiety disorders.
Danysz
Wojciech
W
Merz Pharmaceuticals GmbH, Department of Behavioural Pharmacology, Eckenheimer Landstrasse 100, Frankfurt am Main, D-30618, Germany. Wojciech.Danysz@merz.de
D000409:Alanine / Q000031:analogs & derivatives; D000818:Animals; D014151:Anti-Anxiety Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D001643:Bridged Bicyclo Compounds / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D011355:Prodrugs / Q000627:therapeutic use*; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*; D013329:Structure-Activity Relationship
C503966:2-((2'-amino)propionyl)aminobicyclo(3.1.0)hexane-2,6-dicarboxylic acid; D014151:Anti-Anxiety Agents; D001643:Bridged Bicyclo Compounds; D011355:Prodrugs; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; D000409:Alanine; C104753:eglumetad